The study objective was to evaluate the potential of Biofield Treatment on novel proprietary formulation for skin health using HFF-1, HaCaT, and B16-F10 cells. The test formulation and DMEM were divided into two parts. One part received Biofield Treatment by Gopal Nayak and defined as Biofield Treated (BT) sample, while other part was denoted as untreated (UT) sample. MTT assay showed more than 70% cell viability, suggested the test formulation were safe and nontoxic. BrdU data showed an increased cell proliferation by 170%, 170%, and 212% at 0.1 µg/mL in UT-DMEM + BT-Test formulation, BT-DMEM + UT-Test formulation, and BT-DMEM + BT-Test formulation, respectively than untreated group. Collagen was significantly increased by 140.8% at 5 µg/mL in UT-DMEM + BT-Test formulation than untreated. Elastin was significantly increased by 233.3%, 313.3%, and 637.8% at 0.01 µg/mL in UT-DMEM + BT-Test formulation, BT-DMEM + UT-Test formulation, and BT-DMEM + BT-Test formulation, respectively than untreated. Hyaluronic acid in UT-DMEM + BT-Test formulation, BT-DMEM + UT-Test formulation, and BT-DMEM + BT-Test formulation was significantly increased by 191.8%, 461.0%, and 322.5%, respectively at 0.01 µg/mL than untreated. Melanin synthesis was significantly inhibited by 44.7% (10 µg/mL) and 45.2% (10 µg/mL) in UT-DMEM + BT-Test formulation and BT-DMEM + UT-Test formulation, respectively contrast to untreated. Anti-wrinkling activity was improved with increased cell viability by 88.9% and 92.9% at 1 and 25 µg/mL, respectively in BT-DMEM + UT-Test formulation than untreated. Cell viability was significantly increased by 97.6% and 75.16% at 0.1 and 1 µg/mL, respectively in BT-DMEM + BT-Test formulation than untreated. The UT-DMEM + BT-Test formulation showed increased cellular migration by 2722.2% (0.01 µg/mL) in HaCaT cells than untreated. Overall, result suggests that the Trivedi Effect® has shown significant beneficial effects on skin health parameters that might lead to its potential use in various aging-related disorders, psoriasis, seborrheic dermatitis, skin cancer, rashes from bacterial or fungal infections, and many more skin diseases.
Comments: 12 Pages.
[v1] 2019-08-10 07:38:57
Unique-IP document downloads: 1 times
Vixra.org is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. Vixra.org will not be responsible for any consequences of actions that result from any form of use of any documents on this website.
Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.